The prevalence of overweight and obesity in people with type 1 diabetes has increased significantly, presenting additional psychosocial challenges that vary by gender. This study investigates the relationship between BMI and psychosocial outcomes in adult men and women with type 1 diabetes.
Methods
This cross-sectional analysis used data from people with type 1 diabetes in the BETTER registry, stratified by gender and categorized into BMI groups (<25, 25–29.9, ≥ 30 kg/m2). Psychosocial outcomes included depression, diabetes distress, and stigmatization related to diabetes. One-way ANOVA assessed differences between BMI groups by gender. Multivariable logistic regression then analyzed gender differences within each BMI group, adjusting for age and HbA1c.
Results
Among 1028 participants (66 % women, mean BMI 26.4 ± 5.1 kg/m2, mean age 45.4 ± 15.0 years), 460 adults (45 %) had a BMI < 25, 356 (35 %) between 25–29.9, and 212 (21 %) ≥ 30 kg/m2. Women in the ≥ 30 kg/m2 group, compared to the < 25 kg/m2 group, had more symptoms of depression, more drug prescriptions for depression/anxiety, and higher diabetes distress (p < 0.001 for all). In men, psychosocial outcomes did not differ significantly across BMI groups. Multivariable regression showed women were more likely than men to report prescriptions for depression/anxiety and high diabetes distress, particularly in the higher BMI groups.
Conclusions
In adults living with type 1 diabetes, higher BMI is associated with adverse psychosocial outcomes, particularly in women. Gender-specific interventions addressing mental health, stigma, and weight management could be beneficial to improve overall well-being.
{"title":"Gender differences in psychosocial outcomes according to BMI among adults living with type 1 diabetes: A cross-sectional BETTER analysis","authors":"Anne Bonhoure , Marie-Laure Lalanne-Mistrih , Meryem Talbo , Valérie Boudreau , Virginie Messier , Aude Bandini , Laurence Secours , Sonia Fontaine , Anne-Sophie Brazeau , Rémi Rabasa-Lhoret","doi":"10.1016/j.jcte.2025.100400","DOIUrl":"10.1016/j.jcte.2025.100400","url":null,"abstract":"<div><h3>Aims</h3><div>The prevalence of overweight and obesity in people with type 1 diabetes has increased significantly, presenting additional psychosocial challenges that vary by gender. This study investigates the relationship between BMI and psychosocial outcomes in adult men and women with type 1 diabetes.</div></div><div><h3>Methods</h3><div>This cross-sectional analysis used data from people with type 1 diabetes in the BETTER registry, stratified by gender and categorized into BMI groups (<25, 25–29.9, ≥ 30 kg/m<sup>2</sup>). Psychosocial outcomes included depression, diabetes distress, and stigmatization related to diabetes. One-way ANOVA assessed differences between BMI groups by gender. Multivariable logistic regression then analyzed gender differences within each BMI group, adjusting for age and HbA1c.</div></div><div><h3>Results</h3><div>Among 1028 participants (66 % women, mean BMI 26.4 ± 5.1 kg/m<sup>2</sup>, mean age 45.4 ± 15.0 years), 460 adults (45 %) had a BMI < 25, 356 (35 %) between 25–29.9, and 212 (21 %) ≥ 30 kg/m<sup>2</sup>. Women in the ≥ 30 kg/m<sup>2</sup> group, compared to the < 25 kg/m<sup>2</sup> group, had more symptoms of depression, more drug prescriptions for depression/anxiety, and higher diabetes distress (p < 0.001 for all). In men, psychosocial outcomes did not differ significantly across BMI groups. Multivariable regression showed women were more likely than men to report prescriptions for depression/anxiety and high diabetes distress, particularly in the higher BMI groups.</div></div><div><h3>Conclusions</h3><div>In adults living with type 1 diabetes, higher BMI is associated with adverse psychosocial outcomes, particularly in women. Gender-specific interventions addressing mental health, stigma, and weight management could be beneficial to improve overall well-being.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"41 ","pages":"Article 100400"},"PeriodicalIF":4.2,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144221828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-11DOI: 10.1016/j.jcte.2025.100399
Betina Biagetti , Esteban Cordero Asanza , Carlos Pérez-López , Víctor Rodríguez Berrocal , Almudena Vicente , Cristina Lamas , Fernando Guerrero-Pérez , Andreu Simó-Servat , Guillermo Serra , Ana Irigaray Echarri , M. Dolores Ollero , Inmaculada González Molero , Rocío Villar-Taibo , María Dolores Moure Rodríguez , Pablo García-Feijoo , María Noelia Sánchez Ramirez , Alba Gutiérrez Hurtado , Vanessa Capristan-Díaz , Rosa Camara , Marta Gallach , Marta Araujo-Castro
Background
Pituitary apoplexy (PA) is a rare but potentially life-threatening condition. While conservative management is an option in selected cases, predictors of conversion to surgery after initial conservative management remain unclear.
Objective
To identify predictors of transitioning to surgery in PA who were initially managed conservatively, and to assess the timing and impact of surgical conversion.
Methods
This multicenter observational study included 134 patients with PA initially managed conservatively. Patients were categorized into successful conservative management (no surgery or surgery scheduled after 30 days) and conversion to surgery (surgery within 8–30 days). Logistic and Cox regression analyses were performed to identify predictors of conversion to surgery and time to transition, respectively.
Results
Among the 134 patients enrolled, the median age was 61.4 years (interquartile range: 16.0) years and 93 (69.4 %) men], 69 (51.5 %) ultimately required surgery, with most transitions occurring within the first two weeks. In logistic regression analysis, larger tumor size (OR: 1.09, 95 % CI: 1.02–1.16) and higher BMI (OR: 1.11, 95 % CI: 1.01–1.22) were independently associated with conversion to surgery. However, Cox regression did not identify any variables predicting time to transition. Additionally, patients who converted to surgery had a significantly longer hospital stay (21.0 vs. 7.5 days, p < 0.01).
Conclusion
Half of the patients initially managed conservatively required convertion to surgery. Tumor size and BMI were associated with an increased likelihood of surgery, but no factors predicted when surgery would occur, suggesting that the decision to conversion to surgery may be influenced by multiple clinical factors rather than a single determinant.
{"title":"Predictors of conversion to surgery in pituitary apoplexy: Insights from a Spanish multicenter observational study","authors":"Betina Biagetti , Esteban Cordero Asanza , Carlos Pérez-López , Víctor Rodríguez Berrocal , Almudena Vicente , Cristina Lamas , Fernando Guerrero-Pérez , Andreu Simó-Servat , Guillermo Serra , Ana Irigaray Echarri , M. Dolores Ollero , Inmaculada González Molero , Rocío Villar-Taibo , María Dolores Moure Rodríguez , Pablo García-Feijoo , María Noelia Sánchez Ramirez , Alba Gutiérrez Hurtado , Vanessa Capristan-Díaz , Rosa Camara , Marta Gallach , Marta Araujo-Castro","doi":"10.1016/j.jcte.2025.100399","DOIUrl":"10.1016/j.jcte.2025.100399","url":null,"abstract":"<div><h3>Background</h3><div>Pituitary apoplexy (PA) is a rare but potentially life-threatening condition. While conservative management is an option in selected cases, predictors of conversion to surgery after initial conservative management remain unclear.</div></div><div><h3>Objective</h3><div>To identify predictors of transitioning to surgery in PA who were initially managed conservatively, and to assess the timing and impact of surgical conversion.</div></div><div><h3>Methods</h3><div>This multicenter observational study included 134 patients with PA initially managed conservatively. Patients were categorized into successful conservative management (no surgery or surgery scheduled after 30 days) and conversion to surgery (surgery within 8–30 days). Logistic and Cox regression analyses were performed to identify predictors of conversion to surgery and time to transition, respectively.</div></div><div><h3>Results</h3><div>Among the 134 patients enrolled, the median age was 61.4 years (interquartile range: 16.0) years and 93 (69.4 %) men], 69 (51.5 %) ultimately required surgery, with most transitions occurring within the first two weeks. In logistic regression analysis, larger tumor size (OR: 1.09, 95 % CI: 1.02–1.16) and higher BMI (OR: 1.11, 95 % CI: 1.01–1.22) were independently associated with conversion to surgery. However, Cox regression did not identify any variables predicting time to transition. Additionally, patients who converted to surgery had a significantly longer hospital stay (21.0 vs. 7.5 days, p < 0.01).</div></div><div><h3>Conclusion</h3><div>Half of the patients initially managed conservatively required convertion to surgery. Tumor size and BMI were associated with an increased likelihood of surgery, but no factors predicted when surgery would occur, suggesting that the decision to conversion to surgery may be influenced by multiple clinical factors rather than a single determinant.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"40 ","pages":"Article 100399"},"PeriodicalIF":4.2,"publicationDate":"2025-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143942251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-10DOI: 10.1016/j.jcte.2025.100398
Lily Deng, Amy S. Shah, Mansa Krishnamurthy
Background
Identifying Maturity-onset diabetes of the young (MODY) is essential as treatment differs from other forms of diabetes. Clinical characteristics and MODY probability calculator (MPC) scores were evaluated in patients with MODY.
Methods
Retrospective chart review using MODY diagnoses and genetic testing was performed to identify patients with MODY gene variants at a large, pediatric tertiary referral center. Demographics, islet autoantibodies, and co-morbidities were evaluated with treatment change after diagnosis of MODY. Probability scores were calculated using the MPC.
Results
Thirty-nine patients were identified with MODY. MODY comprised 1 % of the population with diabetes. Mean age and HbA1c at diagnosis were 12.2 years and 7.9 %, respectively. Positive islet cell autoantibodies were seen in 2 individuals. For race, 23.1 % self-identified as Hispanic, Black, or Asian/Pacific Islander. Interestingly, 39.47 % did not require medication at diagnosis while 44.74 %, 10.53 %, and 2.63 % were treated with insulin, Metformin, and GLP-1 RA respectively. Seventy-four percent of patients with MODY had MPC scores of > 75 %. Targeted treatment with sulfonylureas was used for 38 % of total patients who remained on medication, and 20.5 % of patients were able to discontinue medication. Average HbA1c decreased for all patients with MODY regardless of medication treatment type at follow up.
Conclusions
Our data reveals that the presence of positive islet cell antibodies may not preclude a diagnosis of MODY if there is a strong clinical suspicion. High MPC scores correlated with diagnoses of MODY except in patients with insulin dependence. Diagnosis of MODY led to targeted treatment changes.
{"title":"Genetic variants and characterization of MODY in a single, large pediatric referral center","authors":"Lily Deng, Amy S. Shah, Mansa Krishnamurthy","doi":"10.1016/j.jcte.2025.100398","DOIUrl":"10.1016/j.jcte.2025.100398","url":null,"abstract":"<div><h3>Background</h3><div>Identifying Maturity-onset diabetes of the young (MODY) is essential as treatment differs from other forms of diabetes. Clinical characteristics and MODY probability calculator (MPC) scores were evaluated in patients with MODY.</div></div><div><h3>Methods</h3><div>Retrospective chart review using MODY diagnoses and genetic testing was performed to identify patients with MODY gene variants at a large, pediatric tertiary referral center. Demographics, islet autoantibodies, and co-morbidities were evaluated with treatment change after diagnosis of MODY. Probability scores were calculated using the MPC.</div></div><div><h3>Results</h3><div>Thirty-nine patients were identified with MODY. MODY comprised 1 % of the population with diabetes. Mean age and HbA1c at diagnosis were 12.2 years and 7.9 %, respectively. Positive islet cell autoantibodies were seen in 2 individuals. For race, 23.1 % self-identified as Hispanic, Black, or Asian/Pacific Islander. Interestingly, 39.47 % did not require medication at diagnosis while 44.74 %, 10.53 %, and 2.63 % were treated with insulin, Metformin, and GLP-1 RA respectively. Seventy-four percent of patients with MODY had MPC scores of > 75 %. Targeted treatment with sulfonylureas was used for 38 % of total patients who remained on medication, and 20.5 % of patients were able to discontinue medication. Average HbA1c decreased for all patients with MODY regardless of medication treatment type at follow up.</div></div><div><h3>Conclusions</h3><div>Our data reveals that the presence of positive islet cell antibodies may not preclude a diagnosis of MODY if there is a strong clinical suspicion. High MPC scores correlated with diagnoses of MODY except in patients with insulin dependence. Diagnosis of MODY led to targeted treatment changes.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"40 ","pages":"Article 100398"},"PeriodicalIF":4.2,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143942250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-24DOI: 10.1016/j.jcte.2025.100396
Sobrina S. Mohammed , Daniel Mettman , Mariana Garcia-Touza , Maricel Ridella , Betty Drees
Objective
This study aimed to assess the false negative rate (FNR) and concordance of pre-operative ThyGeNEXT®+ThyraMIR® testing in Bethesda category III-V thyroid nodules by comparing results with post-surgical histopathology in thyroid cancer.
Methods
A retrospective review was conducted on 19 patients with Bethesda III-V thyroid nodules who underwent ThyGeNEXT®+ThyraMIR® testing followed by total thyroidectomy with histopathology confirming thyroid cancer. Fine needle aspiration (FNA) cytology, molecular test results, post-surgical histopathology and comprehensive genomic profiling reports (when available) were examined. Concordance was assessed by comparing pre-operative test results (mutations or malignant miRNA expression) to post-surgical histopathology. Discrepancies were further explored using Tempus xT genomic profiling for additional mutations and evaluation of tumor heterogeneity. The FNR was calculated accordingly.
Results
FNR was 10.5 % and there was a high positive concordance with 89.5 % of cases testing positive for mutations or malignant miRNA classifiers. TERT c.-146C>T, NRAS Q61R, and BRAF V600E were among mutations identified. Comprehensive genomic profiling clarified false negatives, revealing insights into the impact of tumor heterogeneity. The miRNA classifier proved effective in detecting malignancy, in cases with subthreshold and RAS mutations or without common genetic alterations. Reliable results were obtained from diverse specimen types.
Conclusions
The low false-negative rate and positive concordance with histopathology highlights the utility of ThyGeNEXT® + ThyraMIR® in enhancing risk stratification and guiding personalized management of indeterminate thyroid nodules and thyroid cancer.
{"title":"False negative rate and concordance of ThyGeNEXT®+ThyraMIR® testing with post-thyroidectomy histopathology","authors":"Sobrina S. Mohammed , Daniel Mettman , Mariana Garcia-Touza , Maricel Ridella , Betty Drees","doi":"10.1016/j.jcte.2025.100396","DOIUrl":"10.1016/j.jcte.2025.100396","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to assess the false negative rate (FNR) and concordance of pre-operative ThyGeNEXT®+ThyraMIR® testing in Bethesda category III-V thyroid nodules by comparing results with post-surgical histopathology in thyroid cancer.</div></div><div><h3>Methods</h3><div>A retrospective review was conducted on 19 patients with Bethesda III-V thyroid nodules who underwent ThyGeNEXT®+ThyraMIR® testing followed by total thyroidectomy with histopathology confirming thyroid cancer. Fine needle aspiration (FNA) cytology, molecular test results, post-surgical histopathology and comprehensive genomic profiling reports (when available) were examined. Concordance was assessed by comparing pre-operative test results (mutations or malignant miRNA expression) to post-surgical histopathology. Discrepancies were further explored using Tempus xT genomic profiling for additional mutations and evaluation of tumor heterogeneity. The FNR was calculated accordingly.</div></div><div><h3>Results</h3><div>FNR was 10.5 % and there was a high positive concordance with 89.5 % of cases testing positive for mutations or malignant miRNA classifiers. TERT c.-146C>T, NRAS Q61R, and BRAF V600E were among mutations identified. Comprehensive genomic profiling clarified false negatives, revealing insights into the impact of tumor heterogeneity. The miRNA classifier proved effective in detecting malignancy, in cases with subthreshold and RAS mutations or without common genetic alterations. Reliable results were obtained from diverse specimen types.</div></div><div><h3>Conclusions</h3><div>The low false-negative rate and positive concordance with histopathology highlights the utility of ThyGeNEXT® + ThyraMIR® in enhancing risk stratification and guiding personalized management of indeterminate thyroid nodules and thyroid cancer.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"40 ","pages":"Article 100396"},"PeriodicalIF":4.2,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143876906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-23DOI: 10.1016/j.jcte.2025.100395
F. Azizi , A.S. Moeini , L. Mehran , S. Masoumi , H. Abdi , S.M. Foroutan , A.E. Saghafinia , A. Amouzegar
Background
Some patients with hypothyroidism lack satisfaction with levothyroxine (LT4) monotherapy, which may be related to lower serum triiodothyronine (T3) and T3/T4 ratios compared to control individuals. This study aimed to evaluate the efficacy and safety of a combination therapy of slow-release T3 (SRT3) and LT4 in patients with primary hypothyroidism compared with LT4 monotherapy.
Methods
Thirty-two hypothyroid women were randomized into two groups of SRT3 + LT4 combination and LT4 monotherapy. Group one received a combination of 15 µg SRT3 and 75 µg LT4, and group two received 100 µg LT4 daily for 8 weeks. Clinical and biochemical measurements were performed at baseline and 4 to 8 weeks after intervention.
Results
There were no significant changes in serum levels of fT4, T3, TSH, and T3/fT4 ratio in the LT4 group at the end of 4 to 8 weeks of study. A statistically significant decrease in fT4 and TSH, and an increase in serum T3 and the T3/fT4 ratio, were observed in the SRT3 + LT4 group. The T3/fT4 ratio reached comparable values to those in normal subjects, 93.63 ± 23.25 vs 95.06 ± 19.44 ng/ng, respectively. The rise in the T3/fT4 ratio 8 weeks after SRT3 + LT4 treatment was between 21 % and 90 % in 10 patients and 1 % and 13 % in 5 patients, with no change in one patient.
Conclusion
The novel combination of SRT3 + LT4 therapy resulted in a significant increase in serum T3 and the T3/fT4 ratio in hypothyroid patients compared to those receiving LT4 monotherapy. The rise in the T3/fT4 ratio was ≥ 21 % in two-thirds of patients; the lack of a significant increase in the T3/fT4 ratio in some patients during SRT3-LT4 combination therapy demands further investigation.
{"title":"Treatment of hypothyroidism with the combination of levothyroxine and slow-release triiodothyronine: a randomized clinical trial","authors":"F. Azizi , A.S. Moeini , L. Mehran , S. Masoumi , H. Abdi , S.M. Foroutan , A.E. Saghafinia , A. Amouzegar","doi":"10.1016/j.jcte.2025.100395","DOIUrl":"10.1016/j.jcte.2025.100395","url":null,"abstract":"<div><h3>Background</h3><div>Some patients with hypothyroidism lack satisfaction with levothyroxine (LT4) monotherapy, which may be related to lower serum triiodothyronine (T3) and T3/T4 ratios compared to control individuals. This study aimed to evaluate the efficacy and safety of a combination therapy of slow-release T3 (SRT3) and LT4 in patients with primary hypothyroidism compared with LT4 monotherapy.</div></div><div><h3>Methods</h3><div>Thirty-two hypothyroid women were randomized into two groups of SRT3 + LT4 combination and LT4 monotherapy. Group one received a combination of 15 µg SRT3 and 75 µg LT4, and group two received 100 µg LT4 daily for 8 weeks. Clinical and biochemical measurements were performed at baseline and 4 to 8 weeks after intervention.</div></div><div><h3>Results</h3><div>There were no significant changes in serum levels of fT4, T3, TSH, and T3/fT4 ratio in the LT4 group at the end of 4 to 8 weeks of study. A statistically significant decrease in fT4 and TSH, and an increase in serum T3 and the T3/fT4 ratio, were observed in the SRT3 + LT4 group. The T3/fT4 ratio reached comparable values to those in normal subjects, 93.63 ± 23.25 vs 95.06 ± 19.44 ng/ng, respectively. The rise in the T3/fT4 ratio 8 weeks after SRT3 + LT4 treatment was between 21 % and 90 % in 10 patients and 1 % and 13 % in 5 patients, with no change in one patient.</div></div><div><h3>Conclusion</h3><div>The novel combination of SRT3 + LT4 therapy resulted in a significant increase in serum T3 and the T3/fT4 ratio in hypothyroid patients compared to those receiving LT4 monotherapy. The rise in the T3/fT4 ratio was ≥ 21 % in two-thirds of patients; the lack of a significant increase in the T3/fT4 ratio in some patients during SRT3-LT4 combination therapy demands further investigation.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"40 ","pages":"Article 100395"},"PeriodicalIF":4.2,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143904509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-08DOI: 10.1016/j.jcte.2025.100393
Cyril Traechslin , Lilian Sewing , Sandra Baumann , Leticia Grize , Janina Vavanikunnel , Marius Kraenzlin , Christoph Henzen , Christian Meier
Background
Sclerostin has been associated with decreased bone turnover in patients with type 2 diabetes mellitus (T2DM). The relationship with bone turnover markers (BTMs) and bone mineral density (BMD) remains unclear. We investigate the relationship between total and bioactive sclerostin measured by three different assays with BTMs and BMD in patients with T2DM compared to healthy controls.
Methods
Baseline data from the cross-sectional multicenter DiabOS-study in Switzerland were analysed. Total and bioactive serum sclerostin levels were measured using three different ELISA-based sclerostin assays (Sclerostin Biomedica, Sclerostin bioactive Biomedica and Sclerostin hsTECO). Sclerostin levels in patients with T2DM and controls were correlated with BTMs and BMD.
Results
Data were analysed from 78 men and postmenopausal women with T2DM and 37 controls (aged 50–75 years). Serum sclerostin levels, adjusted for estimated glomerular filtration rate (eGFR), were higher in patients with T2DM compared to controls with all three assays. In a gender subgroup analysis, bioactive sclerostin levels remained significantly elevated in men with T2DM (T2DM, 106.8 ± 39.9 pmol/L; controls, 88.3 ± 21.3 pmol/L, p = 0.03).
Univariate analysis showed consistent significant correlations with all sclerostin assays for age, eGFR, glycated hemoglobin A1c and diabetes duration. However, in multivariate analysis, eGFR remained the only significant determinant of serum sclerostin levels. Sclerostin levels in patients with T2DM showed significant positive correlations with BMD but no significant correlations with BTMs.
Conclusions
We demonstrate a significant positive association of bioactive serum sclerostin with BMD at all measured sites in patients with T2DM, which may support its utility in the assessment of bone fragility in this population.
研究背景：在2型糖尿病（T2DM）患者中，硬化汀与骨转换减少有关。骨转换标志物（BTMs）和骨矿物质密度（BMD）之间的关系尚不清楚。我们研究了三种不同测定法测量的T2DM患者总硬化蛋白和生物活性硬化蛋白与btm和BMD之间的关系，并与健康对照进行了比较。方法对瑞士横断面多中心diabos研究的基线数据进行分析。采用三种不同的基于elisa的硬化蛋白测定法（sclerostin Biomedica、sclerostin生物活性Biomedica和sclerostin hsTECO）测定血清总硬化蛋白和生物活性硬化蛋白水平。T2DM患者和对照组的硬化蛋白水平与BTMs和BMD相关。结果分析了78名患有T2DM的男性和绝经后女性以及37名对照组（50-75岁）的数据。根据估计的肾小球滤过率（eGFR）调整后的血清硬化蛋白水平在T2DM患者中均高于对照组。在性别亚组分析中，男性T2DM患者的生物活性硬化蛋白水平仍显著升高(T2DM: 106.8±39.9 pmol/L；对照组为88.3±21.3 pmol/L, p = 0.03)。单因素分析显示，年龄、eGFR、糖化血红蛋白A1c和糖尿病病程与所有硬化蛋白检测结果具有一致的显著相关性。然而，在多变量分析中，eGFR仍然是血清硬化蛋白水平的唯一重要决定因素。T2DM患者的硬化蛋白水平与BMD呈显著正相关，而与BTMs无显著相关。结论：我们证明了生物活性血清硬化蛋白与T2DM患者所有测量部位的骨密度显著正相关，这可能支持其在评估该人群骨脆弱性方面的实用性。
{"title":"Association of total and bioactive serum sclerostin levels with bone metabolism in type 2 diabetes mellitus","authors":"Cyril Traechslin , Lilian Sewing , Sandra Baumann , Leticia Grize , Janina Vavanikunnel , Marius Kraenzlin , Christoph Henzen , Christian Meier","doi":"10.1016/j.jcte.2025.100393","DOIUrl":"10.1016/j.jcte.2025.100393","url":null,"abstract":"<div><h3>Background</h3><div>Sclerostin has been associated with decreased bone turnover in patients with type 2 diabetes mellitus (T2DM). The relationship with bone turnover markers (BTMs) and bone mineral density (BMD) remains unclear. We investigate the relationship between total and bioactive sclerostin measured by three different assays with BTMs and BMD in patients with T2DM compared to healthy controls.</div></div><div><h3>Methods</h3><div>Baseline data from the cross-sectional multicenter DiabOS-study in Switzerland were analysed. Total and bioactive serum sclerostin levels were measured using three different ELISA-based sclerostin assays (Sclerostin Biomedica, Sclerostin bioactive Biomedica and Sclerostin hsTECO). Sclerostin levels in patients with T2DM and controls were correlated with BTMs and BMD.</div></div><div><h3>Results</h3><div>Data were analysed from 78 men and postmenopausal women with T2DM and 37 controls (aged 50–75 years). Serum sclerostin levels, adjusted for estimated glomerular filtration rate (eGFR), were higher in patients with T2DM compared to controls with all three assays. In a gender subgroup analysis, bioactive sclerostin levels remained significantly elevated in men with T2DM (T2DM, 106.8 ± 39.9 pmol/L; controls, 88.3 ± 21.3 pmol/L, p = 0.03).</div><div>Univariate analysis showed consistent significant correlations with all sclerostin assays for age, eGFR, glycated hemoglobin A1c and diabetes duration. However, in multivariate analysis, eGFR remained the only significant determinant of serum sclerostin levels. Sclerostin levels in patients with T2DM showed significant positive correlations with BMD but no significant correlations with BTMs.</div></div><div><h3>Conclusions</h3><div>We demonstrate a significant positive association of bioactive serum sclerostin with BMD at all measured sites in patients with T2DM, which may support its utility in the assessment of bone fragility in this population.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"40 ","pages":"Article 100393"},"PeriodicalIF":4.2,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143820467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-07DOI: 10.1016/j.jcte.2025.100392
Wang Shin Lei , XianYan Chen , Lingyu Zhao , Tanicia Daley , Bradley Phillips , Michael R. Rickels , Andrea Kelly , Joseph M. Kindler
Context
Diabetes and bone disease are common in cystic fibrosis (CF) and primarily occur alongside exocrine pancreatic insufficiency (PI). “Incretins,” glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1), augment insulin secretion and regulate bone metabolism. In CF, PI dampens the incretin response. Loss of the insulinotropic effect of GIP in CF was recently identified, but effects on bone are unknown.
Objective
Determine effects of incretins on bone resorption markers in adults with PI-CF.
Design
Secondary analysis of a mechanistic double-blinded randomized placebo-controlled crossover trial including adults ages 18–40 years with PI-CF (n = 25).
Intervention
Adults with PI-CF received either GIP (4 pmol/kg/min) or GLP-1 (1.5 pmol/kg/min) infusion, followed by double-blind randomization to either incretin or placebo infusion. Non-CF healthy controls received double-blind GIP (4 pmol/kg/min) or placebo. Serum C-terminal telopeptide (CTX), a bone resorption marker, was assessed during the infusion over 80 (GIP) or 60 (GLP-1) minutes.
Main Outcome Measures
CTX (mg/dL) concentrations.
Results
In PI-CF, CTX decreased during GIP infusion, but not during placebo (time-by-treatment interaction P < 0.01). GLP-1 did not affect CTX. In non-CF healthy controls, time-by-treatment interaction was not significant (P = 0.23), but CTX decreased during GIP (P = 0.02) but not placebo (P = 0.47).
Conclusions
GIP evokes a bone anti-resorptive effect in people with PI-CF. Since the incretin response is perturbed in PI-CF, and an infusion of GIP lowers bone resorption, the “gut-bone axis” in CF-related bone disease requires attention.
{"title":"Effect of GIP and GLP-1 infusion on bone resorption in glucose intolerant, pancreatic insufficient cystic fibrosis","authors":"Wang Shin Lei , XianYan Chen , Lingyu Zhao , Tanicia Daley , Bradley Phillips , Michael R. Rickels , Andrea Kelly , Joseph M. Kindler","doi":"10.1016/j.jcte.2025.100392","DOIUrl":"10.1016/j.jcte.2025.100392","url":null,"abstract":"<div><h3>Context</h3><div>Diabetes and bone disease are common in cystic fibrosis (CF) and primarily occur alongside exocrine pancreatic insufficiency (PI). “Incretins,” glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1), augment insulin secretion and regulate bone metabolism. In CF, PI dampens the incretin response. Loss of the insulinotropic effect of GIP in CF was recently identified, but effects on bone are unknown.</div></div><div><h3>Objective</h3><div>Determine effects of incretins on bone resorption markers in adults with PI-CF.</div></div><div><h3>Design</h3><div>Secondary analysis of a mechanistic double-blinded randomized placebo-controlled crossover trial including adults ages 18–40 years with PI-CF (n = 25).</div></div><div><h3>Intervention</h3><div>Adults with PI-CF received either GIP (4 pmol/kg/min) or GLP-1 (1.5 pmol/kg/min) infusion, followed by double-blind randomization to either incretin or placebo infusion. Non-CF healthy controls received double-blind GIP (4 pmol/kg/min) or placebo. Serum C-terminal telopeptide (CTX), a bone resorption marker, was assessed during the infusion over 80 (GIP) or 60 (GLP-1) minutes.</div></div><div><h3>Main Outcome Measures</h3><div>CTX (mg/dL) concentrations.</div></div><div><h3>Results</h3><div>In PI-CF, CTX decreased during GIP infusion, but not during placebo (time-by-treatment interaction P < 0.01). GLP-1 did not affect CTX. In non-CF healthy controls, time-by-treatment interaction was not significant (P = 0.23), but CTX decreased during GIP (P = 0.02) but not placebo (P = 0.47).</div></div><div><h3>Conclusions</h3><div>GIP evokes a bone anti-resorptive effect in people with PI-CF. Since the incretin response is perturbed in PI-CF, and an infusion of GIP lowers bone resorption, the “gut-bone axis” in CF-related bone disease requires attention.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"40 ","pages":"Article 100392"},"PeriodicalIF":4.2,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143825630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-04DOI: 10.1016/j.jcte.2025.100389
Leonor M. Gaspar , Catarina I. Gonçalves , Ema L. Nobre , Fernando Fonseca , Cláudia Amaral , João S. Duarte , Luísa Raimundo , Catarina Saraiva , Luísa Cortez , Olinda Marques , Manuel C. Lemos
Mutations in several genes have been associated with familial forms of pituitary adenomas. Sporadic pituitary adenomas (i.e. with no family history or coexistent endocrine tumours) are also occasionally found to result from germline mutations in these genes, especially in young patients with larger tumours. The aim of this study was to determine the frequency of germline mutations in patients with young-onset sporadic pituitary macroadenomas. A cohort of 225 Portuguese patients with sporadic pituitary macroadenomas diagnosed before the age of 40 years was studied by whole exome sequencing (WES) followed by the analysis of a virtual panel of 29 genes that have been associated with predisposition to pituitary adenomas. Pathogenic and likely pathogenic variants were identified in 16 (7.1 %) of patients. The affected genes were AIP (n = 4), PMS2 (n = 4), MEN1 (n = 2), VHL (n = 2), CDH23 (n = 1), MSH2 (n = 1), SDHB (n = 1), and TP53 (n = 1). In patients diagnosed under the ages of 30 and 18 years, the frequency of pathogenic and likely pathogenic variants increased to 9.0 % and 12.0 %, respectively. This is so far the largest multigene analysis of patients with young-onset sporadic pituitary macroadenomas. We confirmed the AIP as the most frequently involved gene, but also uncovered rarer genetic causes of pituitary adenomas. The results may contribute to a better understanding of the genetic landscape of these tumours and help to decide which genes to include in the genetic screening of patients with young-onset pituitary macroadenomas.
{"title":"Germline genetic variants in young-onset sporadic pituitary macroadenomas: A multigene panel analysis","authors":"Leonor M. Gaspar , Catarina I. Gonçalves , Ema L. Nobre , Fernando Fonseca , Cláudia Amaral , João S. Duarte , Luísa Raimundo , Catarina Saraiva , Luísa Cortez , Olinda Marques , Manuel C. Lemos","doi":"10.1016/j.jcte.2025.100389","DOIUrl":"10.1016/j.jcte.2025.100389","url":null,"abstract":"<div><div>Mutations in several genes have been associated with familial forms of pituitary adenomas. Sporadic pituitary adenomas (i.e. with no family history or coexistent endocrine tumours) are also occasionally found to result from germline mutations in these genes, especially in young patients with larger tumours. The aim of this study was to determine the frequency of germline mutations in patients with young-onset sporadic pituitary macroadenomas. A cohort of 225 Portuguese patients with sporadic pituitary macroadenomas diagnosed before the age of 40 years was studied by whole exome sequencing (WES) followed by the analysis of a virtual panel of 29 genes that have been associated with predisposition to pituitary adenomas. Pathogenic and likely pathogenic variants were identified in 16 (7.1 %) of patients. The affected genes were <em>AIP</em> (n = 4), <em>PMS2</em> (n = 4), <em>MEN1</em> (n = 2), <em>VHL</em> (n = 2), <em>CDH23</em> (n = 1), <em>MSH2</em> (n = 1), <em>SDHB</em> (n = 1), and <em>TP53</em> (n = 1). In patients diagnosed under the ages of 30 and 18 years, the frequency of pathogenic and likely pathogenic variants increased to 9.0 % and 12.0 %, respectively. This is so far the largest multigene analysis of patients with young-onset sporadic pituitary macroadenomas. We confirmed the <em>AIP</em> as the most frequently involved gene, but also uncovered rarer genetic causes of pituitary adenomas. The results may contribute to a better understanding of the genetic landscape of these tumours and help to decide which genes to include in the genetic screening of patients with young-onset pituitary macroadenomas.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"40 ","pages":"Article 100389"},"PeriodicalIF":4.2,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143800247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-02DOI: 10.1016/j.jcte.2025.100391
Rosara Bass , Michael Stalvey , George Solomon , Steven Rowe , David Nichols , Sarah Jane Schwarzenberg , Steven Freedman , Rachel Walega , Andrea Kelly
Background/Aims
People with CF (PwCF) have low total, high, and low density lipoprotein cholesterol (TC, HDL-C and LDL-C) and historically have had low prevalence of cardiovascular disease. More recently, cases of acute myocardial infarction are reported in PwCF. The impact of elexacaftor-tezacaftor-ivacaftor (ETI) on cholesterol and triglyceride (TG) concentrations, traditional cardiometabolic risk factors, is unknown.
Methods/Results
TC, LDL-C, HDL-C, and TG concentrations were analyzed from participants enrolled in the observational PROMISE study of clinically prescribed ETI prior to and 12–18 months after initiation. Pre-ETI and follow-up concentrations were compared, and relationships between TC, LDL-C, HDL-C and TG and clinical factors were tested using linear mixed-effect models.
Fasting samples were available for 51 participants (25 M/26F, median age 17.4 y) with pancreatic exocrine insufficiency at baseline and 12–18 months after ETI initiation. TC and HDL-C were higher after 12–18 mo ETI in an unadjusted model, but with adjustment for BMI-Z, only HDL-C remained significantly higher at follow up (p < 0.05). Low HDL-C was the most common abnormality (>50 %), but prevalence of participants meeting criteria for low HDL-C did not differ between timepoints.
Conclusions
In a population of youth and young adults with CF, TC and HDL-C were higher after 12–18 months of ETI, but differences in TC were attenuated with adjustment for BMI-Z. Prevalence of low HDL-C was high at both timepoints.
{"title":"Cholesterol and triglyceride concentrations following 12–18 months of clinically prescribed elexacaftor-tezacaftor-ivacaftor—PROMISE sub-study","authors":"Rosara Bass , Michael Stalvey , George Solomon , Steven Rowe , David Nichols , Sarah Jane Schwarzenberg , Steven Freedman , Rachel Walega , Andrea Kelly","doi":"10.1016/j.jcte.2025.100391","DOIUrl":"10.1016/j.jcte.2025.100391","url":null,"abstract":"<div><h3>Background/Aims</h3><div>People with CF (PwCF) have low total, high, and low density lipoprotein cholesterol (TC, HDL-C and LDL-C) and historically have had low prevalence of cardiovascular disease. More recently, cases of acute myocardial infarction are reported in PwCF. The impact of elexacaftor-tezacaftor-ivacaftor (ETI) on cholesterol and triglyceride (TG) concentrations, traditional cardiometabolic risk factors, is unknown.</div></div><div><h3>Methods/Results</h3><div>TC, LDL-C, HDL-C, and TG concentrations were analyzed from participants enrolled in the observational PROMISE study of clinically prescribed ETI prior to and 12–18 months after initiation. Pre-ETI and follow-up concentrations were compared, and relationships between TC, LDL-C, HDL-C and TG and clinical factors were tested using linear mixed-effect models.</div><div>Fasting samples were available for 51 participants (25 M/26F, median age 17.4 y) with pancreatic exocrine insufficiency at baseline and 12–18 months after ETI initiation. TC and HDL-C were higher after 12–18 mo ETI in an unadjusted model, but with adjustment for BMI-Z, only HDL-C remained significantly higher at follow up (p < 0.05). Low HDL-C was the most common abnormality (>50 %), but prevalence of participants meeting criteria for low HDL-C did not differ between timepoints.</div></div><div><h3>Conclusions</h3><div>In a population of youth and young adults with CF, TC and HDL-C were higher after 12–18 months of ETI, but differences in TC were attenuated with adjustment for BMI-Z. Prevalence of low HDL-C was high at both timepoints.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"40 ","pages":"Article 100391"},"PeriodicalIF":4.2,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143800194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-30DOI: 10.1016/j.jcte.2025.100390
Hui Shi , Ke Ding , Xue Ting Yang , Ting Fan Wu , Jia Yi Zheng , Li Fan Wang , Bo Yang Zhou , Li Ping Sun , Yi Feng Zhang , Chong Ke Zhao , Hui Xiong Xu
Background
Preoperative identification of genetic mutations is conducive to individualized treatment and management of papillary thyroid carcinoma (PTC) patients. Purpose: To investigate the predictive value of the machine learning (ML)-based ultrasound (US) radiomics approaches for BRAF V600E and TERT promoter status (individually and coexistence) in PTC.
Methods
This multicenter study retrospectively collected data of 1076 PTC patients underwent genetic testing detection for BRAF V600E and TERT promoter between March 2016 and December 2021. Radiomics features were extracted from routine grayscale ultrasound images, and gene status-related features were selected. Then these features were included to nine different ML models to predicting different mutations, and optimal models plus statistically significant clinical information were also conducted. The models underwent training and testing, and comparisons were performed.
Results
The Decision Tree-based US radiomics approach had superior prediction performance for the BRAF V600E mutation compared to the other eight ML models, with an area under the curve (AUC) of 0.767 versus 0.547–0.675 (p < 0.05). The US radiomics methodology employing Logistic Regression exhibited the highest accuracy in predicting TERT promoter mutations (AUC, 0.802 vs. 0.525–0.701, p < 0.001) and coexisting BRAF V600E and TERT promoter mutations (0.805 vs. 0.678–0.743, p < 0.001) within the test set. The incorporation of clinical factors enhanced predictive performances to 0.810 for BRAF V600E mutant, 0.897 for TERT promoter mutations, and 0.900 for dual mutations in PTCs.
Conclusion
The machine learning-based US radiomics methods, integrated with clinical characteristics, demonstrated effectiveness in predicting the BRAF V600E and TERT promoter mutations in PTCs.
背景术前基因突变的识别有助于个体化治疗和管理甲状腺乳头状癌（PTC）患者。目的：探讨基于机器学习（ML）的超声（US）放射组学方法对PTC中BRAF V600E和TERT启动子状态（单独和共存）的预测价值。方法本多中心研究回顾性收集了2016年3月至2021年12月期间接受BRAF V600E和TERT启动子基因检测的1076例PTC患者的数据。从常规灰度超声图像中提取放射组学特征，选择与基因状态相关的特征。然后将这些特征纳入9种不同的ML模型，预测不同的突变，并进行最优模型加上具有统计学意义的临床信息。模型经过了训练和测试，并进行了比较。结果与其他8种ML模型相比，基于决策树的美国放射组学方法对BRAF V600E突变的预测效果更好，曲线下面积（AUC）为0.767比0.547-0.675 (p <；0.05)。采用Logistic回归的美国放射组学方法在预测TERT启动子突变方面表现出最高的准确性(AUC, 0.802 vs. 0.525-0.701, p <；0.001)和BRAF V600E和TERT启动子共存突变(0.805 vs. 0.678-0.743, p <；0.001)。临床因素的结合将BRAF V600E突变的预测性能提高到0.810，TERT启动子突变的预测性能提高到0.897，ptc双突变的预测性能提高到0.900。结论基于机器学习的美国放射组学方法，结合临床特征，可有效预测ptc中BRAF V600E和TERT启动子突变。
{"title":"Prediction of BRAF and TERT status in PTCs by machine learning-based ultrasound radiomics methods: A multicenter study","authors":"Hui Shi , Ke Ding , Xue Ting Yang , Ting Fan Wu , Jia Yi Zheng , Li Fan Wang , Bo Yang Zhou , Li Ping Sun , Yi Feng Zhang , Chong Ke Zhao , Hui Xiong Xu","doi":"10.1016/j.jcte.2025.100390","DOIUrl":"10.1016/j.jcte.2025.100390","url":null,"abstract":"<div><h3>Background</h3><div>Preoperative identification of genetic mutations is conducive to individualized treatment and management of papillary thyroid carcinoma (PTC) patients. <em>Purpose</em>: To investigate the predictive value of the machine learning (ML)-based ultrasound (US) radiomics approaches for BRAF V600E and TERT promoter status (individually and coexistence) in PTC.</div></div><div><h3>Methods</h3><div>This multicenter study retrospectively collected data of 1076 PTC patients underwent genetic testing detection for BRAF V600E and TERT promoter between March 2016 and December 2021. Radiomics features were extracted from routine grayscale ultrasound images, and gene status-related features were selected. Then these features were included to nine different ML models to predicting different mutations, and optimal models plus statistically significant clinical information were also conducted. The models underwent training and testing, and comparisons were performed.</div></div><div><h3>Results</h3><div>The Decision Tree-based US radiomics approach had superior prediction performance for the BRAF V600E mutation compared to the other eight ML models, with an area under the curve (AUC) of 0.767 versus 0.547–0.675 (p < 0.05). The US radiomics methodology employing Logistic Regression exhibited the highest accuracy in predicting TERT promoter mutations (AUC, 0.802 vs. 0.525–0.701, p < 0.001) and coexisting BRAF V600E and TERT promoter mutations (0.805 vs. 0.678–0.743, p < 0.001) within the test set. The incorporation of clinical factors enhanced predictive performances to 0.810 for BRAF V600E mutant, 0.897 for TERT promoter mutations, and 0.900 for dual mutations in PTCs.</div></div><div><h3>Conclusion</h3><div>The machine learning-based US radiomics methods, integrated with clinical characteristics, demonstrated effectiveness in predicting the BRAF V600E and TERT promoter mutations in PTCs.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"40 ","pages":"Article 100390"},"PeriodicalIF":4.2,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143767914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号